Horizon scanning: Four phase III studies investigating empagliflozin for type 2 diabetes meet primary end-point
Source: BioSpace.com
Area: News
BioSpace has reported that four late-stage trials evaluating empagliflozin for the treatment of type 2 diabetes met the primary goal of significantly lowering blood sugar levels.
The four pivotal studies from the empagliflozin trial program are:
. Study 1245.20 (n=986) evaluated 10 mg and 25 mg doses of empagliflozin as monotherapy versus placebo for 24 weeks.
. Study 1245.23 (n=1,504) compared 10 mg and 25 mg doses of empagliflozin as an add-on to metformin and metformin plus sulfonylurea versus placebo for 24 weeks.
. Study 1245.19 (n=499) assessed 10 mg and 25 mg doses of empagliflozin as an add-on to pioglitazone and pioglitazone plus metformin versus placebo for 24 weeks.
. Study 1245.36 (n=741) evaluated 25 mg dose of empagliflozin in patients with type 2 diabetes with mild, moderate or severe renal impairment, and 10 mg dose in those with mild renal impairment versus placebo for 52 weeks.
No other data were ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news
More News: Actos | Diabetes | Diabetes Type 2 | Drugs & Pharmacology | Empagliflozin | Endocrinology | Fortamet | Jardiance | Metformin | PET Scan | Study